Mechanism of action of phthalazinone derivatives against rabies virus.

Antiviral therapy In silico drug-target docking Phthalazinone Rabies Replication complex

Journal

Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 14 12 2023
revised: 13 02 2024
accepted: 16 02 2024
medline: 18 3 2024
pubmed: 20 2 2024
entrez: 19 2 2024
Statut: ppublish

Résumé

Rabies, a viral zoonosis, is responsible for almost 59,000 deaths each year, despite the existence of an effective post-exposure prophylaxis. Indeed, rabies causes acute encephalomyelitis, with a case-fatality rate of 100 % after the onset of neurological clinical signs. Therefore, the development of therapies to inhibit the rabies virus (RABV) is crucial. Here, we identified, from a 30,000 compound library screening, phthalazinone derivative compounds as potent inhibitors of RABV infection and more broadly of Lyssavirus and even Mononegavirales infections. Combining in vitro experiments, structural modelling, in silico docking and in vivo assays, we demonstrated that phthalazinone derivatives display a strong inhibition of lyssaviruses infection by acting directly on the replication complex of the virus, and with noticeable effects in delaying the onset of the clinical signs in our mouse model.

Identifiants

pubmed: 38373533
pii: S0166-3542(24)00046-9
doi: 10.1016/j.antiviral.2024.105838
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105838

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Victoire Perraud (V)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France.

Bart Vanderhoydonck (B)

Center for Innovation and Stimulation of Drug Discovery (Cistim) Leuven, Belgium.

Guillaume Bouvier (G)

Institut Pasteur, Université Paris Cité, CNRS UMR3528, Structural Bioinformatics Unit, F-75015, Paris, France.

Guilherme Dias de Melo (G)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France.

Amuri Kilonda (A)

Center for Innovation and Stimulation of Drug Discovery (Cistim) Leuven, Belgium.

Mohamed Koukni (M)

Center for Innovation and Stimulation of Drug Discovery (Cistim) Leuven, Belgium.

Dirk Jochmans (D)

Katholieke Universiteit Leuven, Leuven, Belgium.

Sophie Rogée (S)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France.

Youcef Ben Khalifa (Y)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France.

Lauriane Kergoat (L)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France.

Julien Lannoy (J)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France.

Tina Van Buyten (T)

Katholieke Universiteit Leuven, Leuven, Belgium.

Nadia Izadi-Pruneyre (N)

Institut Pasteur, Université Paris Cité, CNRS UMR3528, Bacterial Transmembrane Systems Unit, F-75015, Paris, France.

Patrick Chaltin (P)

Center for Innovation and Stimulation of Drug Discovery (Cistim) Leuven, Belgium; Centre for Drug Design and Discovery (CD3), Katholieke Universiteit Leuven, Leuven, Belgium.

Johan Neyts (J)

Katholieke Universiteit Leuven, Leuven, Belgium.

Arnaud Marchand (A)

Center for Innovation and Stimulation of Drug Discovery (Cistim) Leuven, Belgium.

Florence Larrous (F)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France. Electronic address: florence.larrous@pasteur.fr.

Hervé Bourhy (H)

Institut Pasteur, Université Paris Cité, Unité Lyssavirus, Epidémiologie et Neuropathologie, WHO Collaborating Centre for Reference and Research on Rabies, F-75015, Paris, France. Electronic address: herve.bourhy@pasteur.fr.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH